EMBECTA CORP.(FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS)
NOVO NORDISK A/S
MEDTRONIC
SANOFI
ELI LILLY AND COMPANY
TANDEM DIABETES CARE, INC.
INSULET CORPORATION
BIOCON
ROCHE DIABETES CARE
HTL-STREFA(SUBSIDIARY OF THE MTD GROUP)
YPSOMED
MEDTRUM TECHNOLOGIES INC.
TERUMO CORPORATION
WOCKHARDT LIMITED
NIPRO
±âŸ ±â¾÷
CEQUR CORPORATION
EOFLOW CO. LTD.
HINDUSTAN SYRINGES & MEDICAL DEVICES LTD
SOOIL DEVELOPMENTS CO. LTD
SUNGSHIM MEDICAL CO. LTD.
B.BRAUN SE
DEBIOTECH SA
JIANGSU DELFU MEDICAL DEVICE CO. LTD
HASELMEIER(A SUBSIDIARY OF MEDMIX)
MANNKIND CORPORATION
Á¦12Àå ºÎ·Ï
KTH
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
The global insulin delivery devices market is projected to reach USD 52.7 billion by 2030 from USD 35.3 billion in 2025, at a CAGR of 8.3% during the forecast period. The insulin delivery devices market is experiencing consistent growth due to several factors. As the global population ages, the prevalence of conditions like diabetes is rising, leading to an increased demand for advanced insulin delivery devices. Additionally, government support and favorable reimbursement schemes are further promoting market growth.
Scope of the Report
Years Considered for the Study
2024-2030
Base Year
2024
Forecast Period
2024-2030
Units Considered
Value (USD billion)
Segments
Type, Disease Type, End User, and Region
Regions covered
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America
Technological advancements in insulin delivery devices, such as the integration of artificial intelligence (AI) and machine learning (ML), have also contributed to this demand. Furthermore, an increase in research and development activities, along with strategic partnerships, is creating additional opportunities for growth in the market.
Overall, the rise in healthcare expenditure focused on diabetes care, combined with the increasing prevalence of diabetes, is fostering new opportunities for market expansion.
The reusable insulin pens segment accounted for the largest share of the insulin delivery devices market, by type of insulin pen, in 2024.
The insulin delivery devices market can be categorized into several types: insulin pens, insulin pumps, insulin syringes, insulin pen needles, and other insulin delivery devices. Within the category of insulin pens, there are two main types: reusable insulin pens and disposable insulin pens. As of 2024, reusable insulin pens held the largest market share.
Reusable insulin pens feature a delivery chamber designed to hold prefilled insulin cartridges. These devices are more cost-effective than disposable insulin pens, leading to their increasing popularity for insulin delivery. They provide significant advantages in terms of affordability, sustainability, and user-friendliness. Additionally, reusable pens offer environmental benefits.
A recent study from the University of Exeter in 2024 reported that approximately four million single-use insulin pens are prescribed annually in England, resulting in about 79 tons of plastic waste and emitting 1,000 tons of carbon dioxide, which is equivalent to the emissions from 250 additional cars on the road. In contrast, reusable insulin pens can significantly reduce this waste, making them a more sustainable option. Consequently, a growing number of end users are opting for reusable insulin pens, driving the segment's growth.
In 2024, the home care settings segment held the largest share of the insulin delivery devices market.
The insulin delivery devices market is categorized by end users into home care settings, hospitals & clinics, and other end users. In 2024, the home care settings segment held the largest market share. This trend is primarily attributed to the increasing preference for self-administration of insulin among patients. One of the main advantages of self-administration is the time and cost savings it offers, as patients can avoid the need for regular visits to healthcare providers for insulin administration. Additionally, self-administration can enhance medication adherence and improve treatment outcomes.
Several factors support this trend, including the launch of advanced, user-friendly delivery devices, manufacturers' focus on providing patient training, and the availability of reimbursements for insulin self-administration in key markets. Over the years, the market has also seen the introduction of technologically advanced pumps and pen needles designed to help patients manage diabetes through self-administration. These new products are designed to deliver precise amounts of insulin using minimally invasive techniques. Collectively, these factors are driving growth in this segment of the market.
In 2024, North America accounted for the largest share of the insulin delivery devices market.
The global market for insulin delivery devices is divided into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest share of this market, primarily due to the rising prevalence of type 1 diabetes in the region. Since type 1 diabetes is dependent on insulin, the increasing number of diabetes patients is driving up demand for insulin delivery devices.
According to the International Diabetes Federation (IDF) Atlas 2025, approximately 1.4 million individuals in the US and 240,000 in Canada were reported to be living with type 1 diabetes in 2024. This growing patient population is fueling a continuous demand for various insulin delivery devices, including pens, pumps, syringes, and pen needles.
Additionally, the North American region is witnessing significant investments in research and development aimed at enhancing insulin delivery technologies. Companies in the area are actively working to improve patient convenience, accuracy, and connectivity of these devices to meet the evolving needs of healthcare professionals and patients. The combination of high disease prevalence, technological advancements, and a robust healthcare infrastructure ensures that North America remains a leading region in the global insulin delivery devices market.
A breakdown of the primary participants referred to for this report is provided below:
By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
By Designation: C-level Executives (50%), Director-level Executives (30%), and Others (20%)
By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (15%), and the Middle East & Africa (10%)
Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.
Note 2: C-level executives include CEOs, CFOs, COOs, and VPs.
Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The players operating in the insulin delivery devices market include Embecta Corp.(US), Novo Nordisk A/S (Denmark), Ypsomed (Switzerland), Medtronic (Ireland), Tandem Diabetes Care, Inc. (US), Sanofi (France), and Eli Lilly and Company (US), Tandem Diabetes Care, Inc. (US), Insulet Corporation (US), Biocon (India), Roche Diabetes Care (Switzerland), HTL-STREFA, a subsidiary of the MTD Group (Poland), Ypsomed (Switzerland), Medtrum Technologies Inc. (China), Terumo Corporation (Japan), Wockhardt Limited (India), Nipro (Japan), Cequr Corporation (Switzerland), Eoflow Co., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd. (India), SOOIL Developments Co., Ltd. (South Korea), SUNGSHIM MEDICAL CO., LTD (South Korea), B. Braun SE (Germany), Debiotech SA (Switzerland), Jiangsu Delfu Medical Device Co., Ltd. (China), Haselmeier, a Medmix company (Germany), and Mankind Corporation (US).
Research Coverage
This report studies the insulin delivery devices market based on type, disease type, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will allow both established companies and smaller or new firms to assess market trends, helping them increase their market share. Companies that purchase the report can employ one or more of the strategies outlined below to enhance their market presence.
This report provides insights on the following pointers:
Analysis of key drivers (growing prevalence of diabetes, technological advancements in insulin delivery devices, government support, and favorable reimbursement schemes), restraints (high cost and lack of reimbursement in developing countries, needle anxiety in patients, and alternative drug delivery methods), opportunities (increasing research and development activities and strategic partnerships, increasing healthcare expenditure on diabetes care, advances in syringe and needle technology, and mandates pertaining to safety-engineered medical needles), challenges (needlestick injuries and misuse of injection pens and lack of interoperability among insulin delivery devices)
Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the insulin delivery devices market
Product Development/Innovation: Comprehensive understanding of the forthcoming trends, research and development initiatives, and product launches within the insulin delivery devices market
Market Development: Complete knowledge about profitable developing regions
Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the insulin delivery devices industry helps to diversify the market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed (Switzerland), Medtronic (Ireland), Tandem Diabetes Care, Inc. (US), Sanofi (France), and Eli Lilly and Company (US)
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 STUDY INCLUSIONS AND EXCLUSIONS
1.3.2 MARKETS COVERED
1.3.3 YEARS CONSIDERED FOR STUDY
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR STUDY
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE-RELATED LIMITATIONS
2.6.2 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 INSULIN DELIVERY DEVICES: MARKET OVERVIEW
4.2 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY TYPE AND COUNTRY